NASDAQ:SCNI Scinai Immunotherapeutics (SCNI) Stock Price, News & Analysis → Dems have chosen Biden replacement? (From Paradigm Press) (Ad) Free SCNI Stock Alerts $3.75 +0.15 (+4.17%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$3.67▼$3.7550-Day Range$3.44▼$5.1952-Week Range$3.19▼$22.70Volume2,434 shsAverage Volume9,488 shsMarket Capitalization$712,481.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrends Get Scinai Immunotherapeutics alerts: Email Address Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About Scinai Immunotherapeutics Stock (NASDAQ:SCNI)Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.Read More SCNI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SCNI Stock News HeadlinesMay 24, 2024 | prnewswire.comScinai Immunotherapeutics Announces Receipt of a Nasdaq Staff Determination Letter Regarding Shareholders' Equity listing requirements and Hearing to Present a Plan for Regaining ComplianceMay 15, 2024 | prnewswire.comScinai Publishes FY 2023 Financial Statements, Files Annual Report on Form 20-F and Provides Business UpdateMay 6, 2024 | finanznachrichten.deScinai Immunotherapeutics Ltd.: Scinai Immunotherapeutics Announces Receipt of Nasdaq Delisting Notification and AppealMay 6, 2024 | prnewswire.comScinai Immunotherapeutics Announces Receipt of Nasdaq Delisting Notification and AppealApril 17, 2024 | morningstar.comScinai Immunotherapeutics Ltd ADR SCNIApril 10, 2024 | prnewswire.comScinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schön of UMGApril 9, 2024 | theglobeandmail.comScinai Immunotherapeutics (NASDAQ: SCNI), Scinai Bioservices Enter MSA with Ayana PharmaApril 8, 2024 | prnewswire.comScinai Immunotherapeutics' CDMO Unit Selected by Ayana Pharma to Provide Drug Development and cGMP Manufacturing ServicesMarch 12, 2024 | finance.yahoo.comScinai leadership to attend BIO-Europe Spring 2024February 29, 2024 | prnewswire.comScinai to showcase its cGMP biologics CDMO and innovative NanoAb pipeline at MIXiii 2024February 13, 2024 | finance.yahoo.comScinai Welcomes Liat Halpert as Head of Business Development and SalesFebruary 3, 2024 | morningstar.comScinai Immunotherapeutics Ltd ADRJanuary 25, 2024 | finance.yahoo.comScinai Immunotherapeutics Congratulates its Co-Lead Scientific Research Collaborator Dirk Görlich on Louis-Jeantet PrizeJanuary 4, 2024 | finance.yahoo.comScinai Immunotherapeutics Announces Closing of Exercise of Outstanding Warrants for $1.69 Million in Gross ProceedsJanuary 4, 2024 | finanznachrichten.deScinai Immunotherapeutics Ltd.: Scinai Immunotherapeutics CEO Issues Letter to ShareholdersJanuary 4, 2024 | finance.yahoo.comScinai Immunotherapeutics CEO Issues Letter to ShareholdersDecember 29, 2023 | msn.comScinai Immunotherapeutics to raise $1.7M through exercise of outstanding warrantsDecember 29, 2023 | finance.yahoo.comScinai Immunotherapeutics Announces Exercise of Outstanding Warrants for $1.69 Million in Gross ProceedsDecember 27, 2023 | finance.yahoo.comScinai (NASDAQ: SCNI) to Host Analyst and Investor Webinar on January 9December 23, 2023 | wsj.comScinai Immunotherapeutics Ltd. ADRDecember 21, 2023 | investing.comScinai Immunotherapeutics Ltd ADR (SCNI)December 12, 2023 | finance.yahoo.comScinai Announces Promising Results in a Psoriatic Human Skin ModelDecember 11, 2023 | finance.yahoo.comStudy published in Antiviral Research supports promise of Scinai Immunotherapeutics' coronavirus NanoAb as aerosolized prophylactic and therapeutic drugNovember 28, 2023 | finance.yahoo.comScinai Immunotherapeutics Regains Compliance with Nasdaq's Stockholders' Equity RuleNovember 20, 2023 | msn.comScinai Immunotherapeutics regains compliance with stockholders' equity ruleSee More Headlines Receive SCNI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Scinai Immunotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today6/02/2024Next Earnings (Estimated)6/03/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:SCNI Previous SymbolNASDAQ:SCNI CUSIPN/A CIK1611747 Webwww.scinai.com Phone972-8-930-2529Fax972-8930-2531Employees33Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($53.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,500,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-64.18% Debt Debt-to-Equity RatioN/A Current Ratio3.06 Quick Ratio3.06 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($24.46) per share Price / Book-0.15Miscellaneous Outstanding Shares190,000Free Float73,000Market Cap$712,481.00 OptionableNot Optionable Beta2.45 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Amir Reichman M.B.A. (Age 48)M.Sc., CEO & Director Comp: $562.5kMr. Elad Mark B.Sc. (Age 41)Eng., M.B.A., Chief Operating Officer Comp: $277.02kDr. Tamar Ben-Yedidia Ph.D. (Age 60)Chief Science Officer Comp: $314.92kMr. Uri Ben-Or CPA (Age 54)CPA, M.B.A., MBA, Chief Financial Officer Comp: $582kDr. Dalit Weinstein Fischer Ph.D.Chief Technology OfficerMr. Joshua E. Phillipson B.Sc.M.B.A., Director of Communications & Investor RelationsLiat HalpertHead of Business Development & SalesMerav KamenskyHead of Quality ControlMore ExecutivesKey CompetitorsFinch Therapeutics GroupNASDAQ:FNCHEloxx PharmaceuticalsNASDAQ:ELOXGamida CellNASDAQ:GMDAQWindtree TherapeuticsNASDAQ:WINTAcorda TherapeuticsNASDAQ:ACORQView All Competitors SCNI Stock Analysis - Frequently Asked Questions How have SCNI shares performed in 2024? Scinai Immunotherapeutics' stock was trading at $5.9540 at the beginning of the year. Since then, SCNI shares have decreased by 37.0% and is now trading at $3.7499. View the best growth stocks for 2024 here. Are investors shorting Scinai Immunotherapeutics? Scinai Immunotherapeutics saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 600 shares, a drop of 93.2% from the April 30th total of 8,800 shares. Based on an average daily trading volume, of 4,800 shares, the days-to-cover ratio is currently 0.1 days. View Scinai Immunotherapeutics' Short Interest. When is Scinai Immunotherapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, June 3rd 2024. View our SCNI earnings forecast. How were Scinai Immunotherapeutics' earnings last quarter? Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) posted its quarterly earnings data on Wednesday, May, 15th. The company reported ($240.00) earnings per share (EPS) for the quarter. When did Scinai Immunotherapeutics' stock split? Scinai Immunotherapeutics's stock reverse split before market open on Tuesday, May 21st 2024. The 1-10 reverse split was announced on Tuesday, May 21st 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 21st 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Scinai Immunotherapeutics? Shares of SCNI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SCNI) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaBiden Nomination CANCELED?The Freeport SocietyWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceThis military-backed stock “owns” AI marketPorter & CompanyExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsWrite this ticker symbol down…StocksToTrade Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scinai Immunotherapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
